{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-032825","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.067186+00:00","generated_at":"2026-06-06T03:28:32.956007+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CRISPR Therapeutics' CASGEVY receives EU conditional approval for sickle cell disease and beta thalassemia","bullets":["European Commission granted conditional marketing authorization for CASGEVY (exa-cel).","Indicated for patients 12+ with severe sickle cell disease or transfusion-dependent beta thalassemia.","Eligible when HSCT is appropriate and no HLA-matched related donor is available.","CMA valid for one year, renewable annually with ongoing data review.","CASGEVY is a CRISPR/Cas9 gene-edited therapy jointly developed with Vertex."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-032825","json":"https://secwatch.observer/filing/0001193125-24-032825.json","markdown":"https://secwatch.observer/filing/0001193125-24-032825.md","text":"https://secwatch.observer/filing/0001193125-24-032825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000119312524032825/0001193125-24-032825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000119312524032825/d787773d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:28:32.956007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}